Cell therapy has arisen as a leading approach to tackle tissue regeneration, through direct transplantation of cells to compensate for disease-related functional loss. Ideally, healthy cells can be extracted from the patient or donor and expanded ex vivo for transplantation; however, achieving therapeutic quality and quantity in ex vivo cell cultures has proved challenging across all cell therapies.
Despite the 2007 breakthrough discovery for converting a somatic cell into an induced pluripotent stem cell (iPSC) using transcription factors (TFs), the requirement to recapitulate biological pathways in the reprogramming of iPSCs and inability to optimize through experimental trial and error has proved limiting. The human genome project identified over 50,000 genes in total, including over 20,000 protein-coding genes. In any given cell, thousands of genes are expressed at any given time. The number of possible combinations exceeds the number of stars in the galaxy, rendering even high-throughput experimental approaches impractical.
Join our speakers, Aida Moreno-Moral and Pierre-Louis Joffrin, to explore how new approaches can enhance existing stem-cell forward reprogramming methods, bypass development pathways altogether for the development of ex vivo cell therapies – and facilitate an entirely new class of in vivo reprogramming therapies.
In this webinar, we will discuss:
- The approaches and challenges associated with the delivery of cell therapies.
- What lies on the road ahead for cell therapy
- How harnessing computational biology will drive the development of future cell and gene therapy products
- Applying Mogrify® in cell & gene therapy: opportunities to transform ex vivo cell therapy programs or pioneer in vivo reprogramming therapies.
Find more details on the webinar and register here.